MUNICH / PENZBERG - Roche, the world’s largest biotechnology company, is investing over 200 million euros in its Penzberg site. The construction of a new diagnostics production facility will create 50 new, top-quality jobs in the State. Bavaria’s Minister of Economic Affairs, Martin Zeil, welcomed this further major investment by the company: “I am very pleased at the Group’s decision. It once again reaffirms its commitment to Bavaria as an excellent research and production location.”
Since it was taken over in 1998 by Boehringer Mannheim, the Roche Group has invested over two billion euros in the Penzberg biotechnology centre and created more than 2,500 jobs. 120 people will be employed in the new ‘Diagnostics Operations Complex II’ facility (DOC II) now planned, where reagents will be produced for diagnostic tests that play a key role in the diagnosis and treatment of many diseases, including life-threatening conditions such as heart attack, heart failure, hepatitis and cancer. The new building is to be commissioned in December 2014. “We are glad that we can make this investment in Bavaria”, commented Thomas Schmid, spokesman of the executive committee of Roche Diagnostics GmbH. “Key arguments for the decision by the Group’s Management and Board of Directors to invest in Penzberg were the competence that has developed over many years, the experience as well as the sustained pioneering spirit of its workforce and not least the prevailing productive environment in the biotechnology centre.”
Headquartered in Basel, Switzerland, Roche is a leading, research-oriented company specialising in the two fields of pharmaceuticals and diagnostics. In 2011, Roche employed a workforce of over 80,000 worldwide and invested more than eight billion francs in research and development. The Group generated a sales revenue of 42.5 billion francs. Roche Penzberg in Upper Bavaria, where close on 5,000 people are employed, is the Group’s largest site for biotech research, development and production in Europe. It is the only Roche site combining research, development and production facilities for both the Pharmaceuticals and the Diagnostics Divisions.